Class Action Filed Against Aardvark Therapeutics Over Securities Allegations

NEW YORK, Sept. 18, 2026 /CourierPR/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers. The lawsuit seeks to recover damages on behalf of all persons and entities that purchased or otherwise acquired Aardvark securities between February 13, 2025, and May 14, 2026, both dates inclusive.

The Complaint alleges that the Offering Documents for Aardvark Therapeutics, Inc.'s February 13, 2025, initial public offering (IPO) were negligently prepared and contained untrue statements of material fact or omitted to state other facts necessary to make the statements not misleading. Additionally, the Complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that ARD-101, the company's key product, was less safe than defendants had led investors to believe. As a result, ARD-101's clinical, regulatory, and commercial prospects were overstated.

According to the press release, the lawsuit is aimed at holding Aardvark Therapeutics, Inc. and its officers accountable for these alleged violations of the federal securities laws. Investors who purchased or otherwise acquired Aardvark securities during the Class Period are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/aardvark-therapeutics-inc-aard-class_action_lawsuit.

Bronstein, Gewirtz & Grossman, LLC, is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide.

If you suffered a loss in Aardvark Therapeutics, Inc. securities, you have until October 13, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. For more information, you can contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911.

The lawsuit seeks to address the alleged misrepresentations and omissions in the Offering Documents and the misleading statements made by the company and its officers. The firm is urging investors to take action to protect their interests and potentially recover their losses. Investors are encouraged to review the Complaint and consider joining the lawsuit to seek justice and compensation.